Corvus Pharmaceuticals appoints Richard van den Broek to Board, effective April 8, 2025

Corvus Pharmaceuticals, Inc.

Richard van den Broek appointed as Class II director, term expiring at 2027 annual meeting.
Appointed to Audit Committee ($10k annual) and Nominating Committee ($4k annual) effective April 8, 2025.
Will receive $35k annual board retainer, prorated for current quarter, plus initial option for 30,000 shares.
Will enter into standard indemnification agreement for directors and officers.
Compensation consistent with company's non-employee director compensation program.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Richard van den Broek

Director

CRVS · Corvus Pharmaceuticals, Inc.

Effective: 2025-04-08
Filed: April 9, 2025, 7:59 PM ET

appointed Richard van den Broek to the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard van den Broek was appointed as Director at Corvus Pharmaceuticals, Inc..

Action: appointed
Role: Director

Exact text from the filing

appointed Richard van den Broek to the Board.

View on SEC.gov

Corvus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-25-002110

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.